Figure 2 . Line plots illustrating UAS7 and CU-QoL Total Score at baseline and at each successive study visit. Differences in UAS7 between Visit 5 (4 weeks after last benralizumab dose) vs. Visit 0 or 1 (baseline) or vs. Visit 2 (post-placebo visit) are summarized for the 9 subjects completing the study; similar data for CU-QoL total score is shown for 9 subject completing the study and the intent to treat analysis for all 12 subjects enrolled.